Ieuan Jones

1.4k total citations
29 papers, 1.0k citations indexed

About

Ieuan Jones is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Ieuan Jones has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Physiology, 12 papers in Pulmonary and Respiratory Medicine and 8 papers in Immunology and Allergy. Recurrent topics in Ieuan Jones's work include Asthma and respiratory diseases (13 papers), Allergic Rhinitis and Sensitization (8 papers) and Respiratory and Cough-Related Research (4 papers). Ieuan Jones is often cited by papers focused on Asthma and respiratory diseases (13 papers), Allergic Rhinitis and Sensitization (8 papers) and Respiratory and Cough-Related Research (4 papers). Ieuan Jones collaborates with scholars based in United Kingdom, Switzerland and United States. Ieuan Jones's co-authors include Ferdinand C. Breedveld, John P. Kirkpatrick, Josef S Smolen, Claire Owen, A. Groenewegen, Philip J. Lowe, Andrej Skerjanec, Suzanne Maahs, David Floch and María Cristina De Salvo and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, European Respiratory Journal and Thorax.

In The Last Decade

Ieuan Jones

28 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ieuan Jones United Kingdom 13 455 308 244 223 206 29 1.0k
Wladimir Szpirt Denmark 15 237 0.5× 180 0.6× 108 0.4× 212 1.0× 46 0.2× 37 1.2k
Chuang‐Wei Wang Taiwan 21 637 1.4× 130 0.4× 75 0.3× 263 1.2× 62 0.3× 63 1.5k
May Mo United States 9 107 0.2× 842 2.7× 191 0.8× 374 1.7× 414 2.0× 21 1.3k
Bart Frederick United States 12 188 0.4× 112 0.4× 148 0.6× 611 2.7× 29 0.1× 19 1.0k
Yoshinori Umezawa Japan 23 252 0.6× 193 0.6× 69 0.3× 857 3.8× 41 0.2× 71 1.3k
Tiffani K. Hamilton United States 14 165 0.4× 129 0.4× 38 0.2× 829 3.7× 127 0.6× 25 1.2k
Tetsuzo Sugisaki Japan 16 177 0.4× 47 0.2× 72 0.3× 213 1.0× 63 0.3× 56 977
H. Kiener Austria 14 151 0.3× 48 0.2× 56 0.2× 183 0.8× 39 0.2× 32 717
B Berner Germany 12 285 0.6× 113 0.4× 51 0.2× 742 3.3× 36 0.2× 15 1.0k
Eric Lee United States 11 80 0.2× 48 0.2× 176 0.7× 188 0.8× 110 0.5× 28 1.2k

Countries citing papers authored by Ieuan Jones

Since Specialization
Citations

This map shows the geographic impact of Ieuan Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ieuan Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ieuan Jones more than expected).

Fields of papers citing papers by Ieuan Jones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ieuan Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ieuan Jones. The network helps show where Ieuan Jones may publish in the future.

Co-authorship network of co-authors of Ieuan Jones

This figure shows the co-authorship network connecting the top 25 collaborators of Ieuan Jones. A scholar is included among the top collaborators of Ieuan Jones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ieuan Jones. Ieuan Jones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Xu, Yan, Xianbin Tian, Kasra Shakeri‐Nejad, et al.. (2024). Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers. Clinical Pharmacology in Drug Development. 13(6). 611–620. 1 indexed citations
3.
Gauvreau, Gail M., Jens M. Hohlfeld, J. Mark FitzGerald, et al.. (2023). Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. European Respiratory Journal. 61(3). 2201193–2201193. 40 indexed citations
4.
Singh, Dave, Jim M. Wild, Dinesh Saralaya, et al.. (2022). Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial. Respiratory Research. 23(1). 26–26. 8 indexed citations
5.
Kazani, Shamsah, David J. Rowlands, Julie Milojevic, et al.. (2020). Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). Journal of Cystic Fibrosis. 20(2). 250–256. 16 indexed citations
6.
Rowe, Steven M., Ieuan Jones, Mark T. Dransfield, et al.. (2020). <p>Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial</p>. International Journal of COPD. Volume 15. 2399–2409. 32 indexed citations
7.
Beier, Jutta, Henrik Watz, Zuzana Diamant, et al.. (2020). Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial. ERJ Open Research. 7(2). 425–2020. 1 indexed citations
8.
Chapman, Kenneth R., Henrik Watz, Jutta Beier, et al.. (2019). Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma. PA3720–PA3720. 1 indexed citations
9.
10.
Tillmann, Hanns-Christian, Ieuan Jones, Robert Fogel, & Donald Banerji. (2015). QVA149 provides significant symptomatic benefit to COPD patients as measured by a new symptom e-diary: The SHINE study. PA1488–PA1488. 1 indexed citations
11.
Chaker, Adam, Mohamed H. Shamji, Moisés A. Calderón, et al.. (2015). Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti–IL-4: A randomized controlled trial. Journal of Allergy and Clinical Immunology. 137(2). 452–461.e9. 45 indexed citations
12.
Drollmann, Anton, Matthew Brown, Romain Séchaud, et al.. (2014). Effect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics. 52(5). 369–380. 12 indexed citations
13.
Rothenberg, Marc E., Ting Wen, Allison Greenberg, et al.. (2014). Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. Journal of Allergy and Clinical Immunology. 135(2). 500–507. 222 indexed citations
14.
Fisch, Roland, et al.. (2014). Bayesian Design of Proof-of-Concept Trials. Therapeutic Innovation & Regulatory Science. 49(1). 155–162. 37 indexed citations
15.
16.
17.
Smith, Michael K., Ieuan Jones, Mark Morris, Andrew P. Grieve, & Keith Tan. (2006). Implementation of a Bayesian adaptive design in a proof of concept study. Pharmaceutical Statistics. 5(1). 39–50. 37 indexed citations
18.
Smolen, Josef S, et al.. (1995). Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis & Rheumatism. 38(1). 38–43. 216 indexed citations
19.
Jones, Ieuan, M Lowenthal, & M. S. R. Hutt. (1975). FULMINANT TROPICAL SPLENOMEGALY SYNDROME. The Medical Journal of Australia. 2(16). 645–647. 7 indexed citations
20.
Jones, Ieuan, et al.. (1972). Allergy to house-dust mites in the tropics.. BMJ. 3(5829). 764.1–764. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wladimir Szpirt Breakdown of academic impact, for papers by Chuang‐Wei Wang Breakdown of academic impact, for papers by May Mo Breakdown of academic impact, for papers by Bart Frederick Breakdown of academic impact, for papers by Yoshinori Umezawa Breakdown of academic impact, for papers by Tiffani K. Hamilton Breakdown of academic impact, for papers by Tetsuzo Sugisaki Breakdown of academic impact, for papers by H. Kiener Breakdown of academic impact, for papers by B Berner Breakdown of academic impact, for papers by Eric Lee
Rankless by CCL
2026